Department of Hepatic Surgery, National Hepatobiliary and Enteric Surgery Research Center, Ministry of Health, Central South University, Changsha 410008, Hunan Province, China.
World J Gastroenterol. 2012 Aug 21;18(31):4207-14. doi: 10.3748/wjg.v18.i31.4207.
To perform a systematic meta-analysis to investigate the association between X-ray repair cross-complementing group 1 (XRCC1) polymorphisms and hepatocellular carcinoma (HCC) risk.
Relevant studies extracted from PubMed, Embase, Wanfang, VIP and the Chinese National Knowledge Infrastructure databases up to March 2012 were included in the study. Stata software, version 11.0, was used for the statistical analysis. The odds ratios (ORs) and 95% confidence interval (CI) of the XRCC1 polymorphisms in HCC patients were analyzed and compared with healthy controls. The meta-analysis was performed using fixed-effect or random-effect methods, depending on the absence or presence of significant heterogeneity.
Eleven studies with 2075 HCC cases and 2604 controls met our eligibility criteria (four studies, 888 cases and 938 controls for Arg194Trp, four studies, 858 cases and 880 controls for Arg280His, and nine studies, 1845 cases and 2401 controls for Arg399Gln). The meta-analysis revealed no associations between the Arg194Trp and Arg399Gln polymorphisms of the XRCC1 gene and HCC risk under all contrast models (codominant, dominant and recessive models) in the overall analysis and sensitivity analysis (the studies with controls not in the Hardy-Weinberg equilibrium were excluded). For XRCC1 Arg280His polymorphism, the overall analysis revealed the significant association between the His/His genotype and the increased risk of HCC (His/His vs Arg/Arg model, OR: 1.96, 95% CI: 1.03-3.75, P = 0.04). However, sensitivity analysis showed an altered pattern of result and non-significant association (OR: 2.06, 95% CI: 0.67-6.25, P = 0.20). The heterogeneity hypothesis test did not reveal any heterogeneity, and Begg's and Egger's tests did not find any obvious publication bias.
The XRCC1 Arg194Trp and Arg399Gln polymorphisms are not associated with HCC risk. More rigorous association studies are needed to verify the involvement of XRCC1 Arg280His polymorphism in HCC susceptibility.
系统地进行荟萃分析，以调查 X 射线修复交叉互补组 1（XRCC1）多态性与肝细胞癌（HCC）风险之间的关系。
从 PubMed、Embase、万方、VIP 和中国国家知识基础设施数据库中提取截至 2012 年 3 月的相关研究，纳入本研究。使用 Stata 软件，版本 11.0，对 HCC 患者 XRCC1 多态性的比值比（OR）和 95%置信区间（CI）进行分析，并与健康对照组进行比较。根据是否存在显著异质性，采用固定效应或随机效应方法进行荟萃分析。
符合纳入标准的研究共有 11 项，共纳入 2075 例 HCC 患者和 2604 例对照（4 项研究，888 例患者和 938 例对照为 Arg194Trp 多态性，4 项研究，858 例患者和 880 例对照为 Arg280His 多态性，9 项研究，1845 例患者和 2401 例对照为 Arg399Gln 多态性）。荟萃分析显示，在所有对比模型（共显性、显性和隐性模型）下，XRCC1 基因 Arg194Trp 和 Arg399Gln 多态性与 HCC 风险均无关联（总体分析和敏感性分析排除了对照不符合 Hardy-Weinberg 平衡的研究）。对于 XRCC1 Arg280His 多态性，总体分析显示 His/His 基因型与 HCC 风险增加之间存在显著关联（His/His 与 Arg/Arg 模型相比，OR：1.96，95%CI：1.03-3.75，P=0.04）。然而，敏感性分析显示结果模式发生了变化，且无显著关联（OR：2.06，95%CI：0.67-6.25，P=0.20）。异质性假设检验未发现任何异质性，Begg 和 Egger 检验未发现明显的发表偏倚。
XRCC1 Arg194Trp 和 Arg399Gln 多态性与 HCC 风险无关。需要更严格的关联研究来验证 XRCC1 Arg280His 多态性是否与 HCC 易感性有关。
